International Stem Cell Corp. (ISCO) Looking to Transform Parkinson’s Disease Treatment with ISC-hpNSC™ Clinical Trial
Last month, International Stem Cell Corp. (OTCQB: ISCO) published the results of its 12-month pre-clinical, non-human primate study demonstrating the safety and efficacy of its proprietary human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC™). These findings highlighted the efficacy of transplanting ISC-hpNSC into non-human primates induced with moderate to severe clinical Parkinson’s disease symptoms, as well as serving as the basis of ISCO’s application to the Australian regulatory authorities to move forward with clinical trials, which was approved in mid-December. “The publication of the data in the peer-reviewed and highly-respected journal, Cell Transplantation, brings to conclusion the preclinical stage of…